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Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of bisphosphonate
therapy, characterised by exposed necrotic bone. The soft tissues of the oral mucosa no longer
provide a protective barrier and MRONJ patients experience pain, infections and difficulties eating.
We hypothesised that hydroxyapatite (Ca5(PO4)3(OH)) could reduce bisphosphonate concentrations
and protect the oral mucosa by exploiting bisphosphonate’s calcium binding affinity. The effect of
zoledronic acid (ZA) and pamidronic acid (PA) on themetabolism of oral fibroblasts, oral keratinocytes
and three-dimensional oral mucosa models was investigated and then repeated in the presence of
hydroxyapatite granules. Without hydroxyapatite, ZA and PA significantly reduced the metabolic
activity of oral cells in a dose-dependent manner. Both drugs reduced epithelial thickness and 30 µM
ZA resulted in loss of the epithelium. Hydroxyapatite granules had a protective effect on oral cells,
with metabolic activity retained. Oral mucosa models retained their multi-layered epithelium when
treated with ZA in the presence of hydroxyapatite granules and metabolic activity was comparable to
controls. These results demonstrate hydroxyapatite granules protected oral soft tissues from damage
caused by bisphosphonate exposure. Porous hydroxyapatite granules are currently used for socket
preservation and this data suggests their potential to prevent MRONJ in at-risk patients.
Keywords: osteonecrosis; osteonecrosis of the jaw; fibroblasts; keratinocytes; pamidronic acid;
pamidronate; zoledronic acid; zoledronate; BRONJ; MRONJ
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is a disease defined by jawbone necrosis
and exposure through the overlying soft tissue. The exposed bone causes pain, is prone to recurrent
infection and leads to difficulty with eating, drinking and speech [1]. MRONJ commonly develops
in patients following wounding of the jaw and, in the majority of cases, follows a tooth extraction.
The medications most commonly associated with MRONJ are bisphosphonates (BPs). However, other
anti-resorptives and anti-angiogenic medications have been linked to the disease [2]. Incidence is
variable depending on the medication used, therapy length and other risk factors including poor oral
hygiene. The risk of developing MRONJ ranges from 1% to 10% for patients prescribed BPs for bone
metastases, and 0.01% to 0.001% for those treated for osteoporosis [3]. MRONJ is currently without an
effective treatment [2].
BPs act either by inhibition of adenosine triphosphate-dependent metabolic pathways or the
mevalonate pathway, depending on their chemical structure, ultimately leading to cell death [4,5].
BPs bind to the calcium in hydroxyapatite avidly, causing a preferential effect on the osteoclasts in
bone, and have a prolonged effect once administered [5,6]. Some BPs have half-lives in bone measured
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in years, so ceasing treatment after MRONJ develops or withholding BP treatment prior to dental work
have shown little benefit.
Since it was first described in 2003, devising a treatment for MRONJ has been challenging due to
the relatively low incidence and incomplete knowledge of its pathogenesis [7]. However, incidence
rates are rising [8]. Bone exposure through the soft tissue is the primary clinical feature of MRONJ
and closure of the MRONJ wound has been hypothesised as key to treatment [9]. While most studies
agree that clinically relevant BP concentrations are toxic to oral mucosa cells [10–13], there is a lack of
consensus on the concentration at which this toxicity occurs, and one study has shown that low levels
of BPs can have a positive effect on keratinocytes [14]. Most work has focused on cells in monolayer,
with few studies investigating how BPs affect the oral mucosa in 3D [15–18]. It is therefore important
to further examine this toxicity in a more comprehensive manner.
Several strategies have been investigated to reduce BP action at the wound site. Elsayed et al. [19]
used ethylenediaminetetraacetic acid (EDTA) to chelate ZA from the bone matrix, rescuing osteoclast
function, while Oizumi et al. [20] displaced potent BPs from the bone matrix with low-potency BPs in
MRONJ patients, which promoted the recovery of soft tissues. A recent in vitro study demonstrated
that calcium phosphate-based materials could bind ZA from solution, reducing cytotoxicity in oral
fibroblasts [21]. Hydroxyapatite (HA) is a calcium phosphate-based bone filler material, known to
support bone regeneration, which is currently approved for use in tooth socket repair [22]. In this
study, we hypothesised that HA could bind free BPs, reducing local BP concentrations and preventing
soft tissue toxicity associated with MRONJ development. The focus of our work was to measure BP
toxicity to the oral mucosa in vitro, in both 2D and 3D, and to determine whether HA could inhibit the
soft tissue toxicity caused by BPs.
2. Materials and Methods
2.1. Microscopy
PermaBone® 100% porous HA was kindly provided from Ceramisys Limited (Sheffield, UK) in
the forms of 1–4 mm porous granules (over 80% porosity) and pre-granulated material. The granules
were examined using a stereomicroscope (Zeiss SteREO.V8 with a Zeiss SteREO CL1500 ECO
light source, Oberkochen, Germany) and photographed using a 1.4 megapixel camera (Zeiss ICc 1,
Oberkochen, Germany).
Pre-granulated HAwas examined using scanning electron microscopy (SEM). The HAwas placed
on a carbon tab, gold coated by sputtering and imaged using a scanning electron microscope (Philips
XL-20, Amsterdam, The Netherlands), operated at 13 kV.
2.2. Cell Culture
Human oral fibroblasts were isolated from human oral tissue through overnight incubation in
0.5 mg/mL collagenase A (Roche, Basel, Switzerland), and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 0.01 mg/mL Penicillin/Streptomycin (P/S) and 0.01 mg/mL L-Glutamine
(LG) (all Sigma-Aldrich, Dorset, UK) and 10% foetal calf serum (FCS) (Biosera, East Sussex, UK).
All subjects gave their informed consent for inclusion before they participated in the study. The study
was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the
University of Sheffield Ethics Committee on 1st June 2015 (Reference number 003463).
Human oral keratinocytes, immortalised through transduction (OKF6/TERT 2) [23], were cultured
in keratinocyte serum-free medium with 0.05 mg/mL bovine pituitary extract and 0.005 µg/mL
epidermal growth factor (EGF) (all Gibco, Paisley, UK) and 0.01 mg/mL P/S (Sigma-Aldrich).
These cells were originally isolated by Lindberg and Rheinwald [24] and provided by Dr. James G
Rheinwald. The 3D cell culture took place in Green’s medium—comprised of DMEM and Ham’s F12
nutrient mixture (Sigma-Aldrich) (3:1 ratio) with 0.01 mg/mL P/S, 0.01 mg/mL LG, 5 µg/mL insulin,
5 µg/mL apo transferrin, 4 µg/mL hydrocortisone, 0.625 µg/mL amphotericin B, 0.025 µg/mL adenine,
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8.47 ng/mL cholera toxin, 5 ng/mL EGF and 1.36 ng/mL 3,3,5 tri-iodothyronine (all Sigma-Aldrich) and
10% FCS (BioSera).
2.3. De-Cellularised Dermis Preparation
Split-thickness skin was incubated at 37 ◦C in 1 M NaCl solution (Sigma-Aldrich) for 24 h and the
epithelium was removed to produce de-cellularised dermis (DCD). All subjects gave their informed
consent for inclusion before they participated in the study. The studywas conducted in accordance with
the Declaration of Helsinki, and the protocol was approved by the NHS Research Ethics Committee in
2015 (Amended 14 November 2019) (Reference number 15/YH/0177).
2.4. Bisphosphonates
Pamidronate disodium salt hydrate (PA) (Sigma-Aldrich) and zoledronic acid monohydrate (ZA)
(Sigma-Aldrich) were dissolved in distilled water, aliquoted and stored at −20 ◦C. Clinically relevant
concentrations of BPs were selected based on Scheper et al. [25].
2.5. Two-Dimensional Cell Viability Assays
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) assay
was used to measure cell viability as per the manufacturer’s instructions. Fibroblasts (1.0 × 104 cells
per cm2) and keratinocytes (1.67 × 104 cells per cm2) were seeded and left overnight to adhere.
Cells were then treated with PA- or ZA-containing medium for up to 72 h. Values were normalised to
0 µM at 24 h.
Half maximal inhibitory concentrations (IC50) were calculated based on theMTT data. Values were
first normalised to the control at 72 h, where concentrations were transformed to log10(concentration)
with 0 µM set as 1 × 10−10 µM, and an IC50 was generated.
2.6. Three-Dimensional Cell Culture
Models of the oral mucosa were produced as described previously [26]. Briefly, DCD was cut
into 400 mm2 pieces. Fibroblasts (2.5 × 105) and keratinocytes (1 × 106) were seeded on the DCD in
stainless steel rings. At 0 h the medium was a DMEM and KSFM mixture (1:1), at 24 h half of this
was replaced by Green’s medium, at 48 h the medium was entirely replaced by a KSFM and Green’s
medium mixture (1:1). After seeding for 72 h, the rings were removed, models were quartered and
placed onto a stainless steel grid at air–liquid interface (ALI) in Green’s medium.
A resazurin reduction assay was performed to measure the metabolic activity of the oral mucosa
after 7 days at ALI. Models were then cultured in a BP-containing medium and the resazurin assay
was repeated at days 10 and 14. Models were incubated with resazurin sodium salt (Sigma Aldrich)
(25.1 µg/mL) for 4 h before absorbance readings were taken (absorbance = 562 nm/reference = 630 nm).
Samples were then washed with PBS and placed back at ALI. Values were normalised to those of each
individual model at day 7. At day, 14 samples were fixed in 3.7% formaldehyde (Sigma-Aldrich) and
analysed using standard histology. Photoshop CS2 (Adobe, San Jose, CA, USA) was used to digitally
remove the background from images.
2.7. Hydroxyapatite Binding Assays
A 0.65 g amount of PermaBone® granules (Ceramisys Limited, Sheffield, UK) was sterilised by
autoclave and incubatedwith a BP-containingmedium for 72 h. Cells were treatedwith a BP-containing
medium or a medium incubated with HA and BPs for 72 h and an MTT assay was performed.
Oral mucosa models were seeded as above, halved with a sterile scalpel and placed at ALI for
7 days. Models were treated with either 0 µM control medium or 30 µM ZA from day 7. A 0.65 g
amount of HA granules was placed under the stainless steel grid and a resazurin assay was performed
at days 10 and 14. Samples were then fixed, processed for histology and stained as above.
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2.8. Statistics
Prism 7 (GraphPad, San Diego, CA, USA) was used to perform all statistical analyses. Statistical
significance was defined as p ≤ 0.05. Standard deviation (SD) was used for all error bars. For the 2D and
3D BP viability tests, repeated measures two-way analysis of variance (ANOVA) tests and Dunnett’s
multiple comparison tests were carried out to investigate differences between BPs and control medium
(0 µM) at each time point. One value, identified as a significant outlier (p ≤ 0.001) using Grubb’s test,
was removed from the MTT data. In the HA experiments, post-hoc analysis was performed using
Tukey’s test. Significance was calculated between the control group and each HA group, comparing
the individual BP concentration of the controls with their corresponding concentration in the HA group
(e.g., control 100 µM PA vs. HA granules 100 µM PA).
3. Results
3.1. Microscopy of Hydroxyapatite Granules Confirmed Highly Porous Structure
The HA granules were examined under a stereomicroscope, and pre-granulated HA examined
with SEM to examine their structure. The HA had an open porosity, with macropores of a range of
diameters visible throughout the material (Figure 1).
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Figure 1. (A) A stereomicroscopy image of a PermaBone® hydroxyapatite granule. (B) A scanning
electron microscopy image of pre-granulated PermaBone® hydroxyapatite.
3.2. Clinically Relevant Pamidronic Acid and Zoledronic Acid Concentrations are Toxic to Oral Mucosa Cells
in 2D
The toxicity of PA and ZA was first measured in 2D. Figure 2A shows the response of oral
fibroblasts when cultured in different concentrations of PA over 72 h, normalised to the control (0 µM)
value at 24 h. At 24 h, there were no significant differences in metabolic activity. At 48 h, 100 µM
PA significantly reduced metabolic activity. Both 50 and 100 µM PA significantly lowered fibroblast
metabolic activity after 72 h. The IC50 at 72 h was 43 µM.
When immortalised keratinocytes (OKF6)were cultured in PA, therewere no significant differences
at 24 h (Figure 2B). After 48 h, a dose response was seen, with 100 µM PA significantly reducing
metabolic activity. PA concentrations of 30 µM and above significantly lowered keratinocyte metabolic
activity after 72 h in a dose-dependent manner, and the IC50 was 35 µM.
ZA is a more potent anti-resorptive compared to PA [4] and was shown to be more toxic to
oral mucosa cells. A dose-dependent response was seen with fibroblasts (Figure 2C), with 10 µM
significantly reducing metabolic activity following 72 h culture, and an IC50 of 6 µM.
Figure 2D shows the response of immortalised keratinocytes to ZA. Again, no significance was
found between doses at 24 or 48 h. At 72 h, concentrations of 20 and 50 µM significantly reduced cell
metabolic activity in comparison to the control. The IC50 was 19 µM.
Materials 2020, 13, 2086 5 of 12
ȱŘŖŘŖǰȱŗřǰȱ¡ȱȱȱȱ śȱȱŗŘȱ

ȱ
ȱŘǯȱȱȱ¢ȱȱ ŝŘȱȱ ȱ ȱȱȱ ȱȱ¢ȱȱ
¢ǯȱǻǼȱ
ȱȱȱ ȱȱǰȱǻǼȱȱȱȱ ȱ£ȱ
ǰȱǻǼȱȱȱȱ¢ȱ ȱȱȱȱǻǼȱȱȱ
ȱ¢ȱ ȱ£ȱǯȱȱȱȱŖȱAgȱȱŘŚȱǯȱȱȱ¢ȱ
ȱǯȱȱƽȱřǰȱȱƽȱřǯȱȱȱƽȱȱȱǻǼǯȱȱȱŖȱAgȱȱȱ
ȱȱȱ¢ȱȘȱǂȱŖǯŖśǯȱ
řǯřǯȱȱȱȱȱȱȱȱȱȱȱ¡¢ȱȱȱȱ
ȱȱřȱ
ȱ¢ȱ ȱȱȱ¢ȱȱǰȱȱ ȱȱȱŝȱ¢ȱȱ ȱȱ
ȱȱȱ ȱȱȱŝȱ¢ǯȱȱřȱ ȱȱȱȱȱȱȱ
ȱȱȱ¢ȱȱȱȱȱȱȱȱǯȱȱȱȱǰȱȱ
ȱǰȱȱȱ¢ȱŝȱȱ¢ȱŗŚǯȱȱřȱ ȱȱȱȱȱŗŚȱ¢ȱ
ȱȱǯȱȱřȮȱȱȱ ȱȱȱȱȬȱȱȱ
ȱǰȱȱ¢ȱ ȱȱȱȱȱȱ¢ǯȱ
ȱ ȱ ȱ ŗȱ ȱ ŗŖȱ Agȱ ȱ ȱ ȱ ǰȱ  ȱ ȱ řŖȱ Agȱ ȱ
¢ȱ ȱȱ¢ȱȱ¡¢ȱŗŖƖȱȱŝȱ¢ȱȱȱǻȱřǼǯȱ
ȱ ř	ǰ
ȱȱ ȱŗȱȱŗŖȱAgȱȱ ȱȱ ȱ ȱȱȬȱ
ǯȱȱȱ ȱȱȱřŖȱAgȱȱȱǻȱřǼǯȱ
Figure 2. Cell metabolic activity over 72 h in the presence of bisphosphonates measured by MTT assay.
(A) Human oral fibroblasts with pamidronic acid, (B) human oral fibroblasts with zoledronic acid,
(C) immortalised human oral keratinocytes with pamidronic acid and (D) immortalised human oral
keratinocytes with zoledronic acid. Values normalised to 0 µM at 24 h. One significant outlying value
removed. N = 3, n = 3. Error bars = standard deviation (SD). Significance against 0 µM at each time
point indicated by *p ≤ 0.05.
3.3. Pamidronic Acid and Zoledronic Acid Reduce Epithelial Thickness and Cause Toxicity to the Oral Mucosa
in 3D
To study how BPs affect healthy oral mucosa, models were cultured for 7 days to allow epithelial
stratification before treating with BPs for 7 days. Figure 3A shows that PA had no significant effect on
the metabolic activity of the models in comparison to the control. Values for all samples, including the
control, decreased from day 7 to day 14. Figure 3C shows the epithelial stratification after 14 days
in control medium. Figure 3D–F demonstrate that while PA caused a dose-dependent reduction in
epithelial thickness, differentiated keratinocytes were still present in the superficial layer.
ZA concentrations of 1 and 10 µM had no metabolic effect, while a 30 µM concentration
significantly lowered metabolic activity to approximately 10% after 7 days of treatment (Figure 3B).
Figure 3G,H demonstrate that 1 and 10 µM ZA reduced epithelial thickness in a dose-dependent
manner. No epithelium was present after 30 µM ZA treatment (Figure 3I).
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Figure 3. The metabolic activity of oral mucosa models when treated with (A) pamidronic acid and
(B) zoledronic acid for 7 days after prior culture at ALI in control medium for 7 days, measured
with a resazurin assay. A blank well reading was subtracted before values were normalised to day
7 value for each model, defining day 7 values as 100 % (not shown). N = 3, n = 3. Error bars = SD.
Statistical significance against 0 µM at each time point indicated by * p ≤ 0.05. (C–I) H & E-stained
sections of oral mucosa models seeded with human oral fibroblasts and immortalised human oral
keratinocytes cultured at ALI for 7 days in control medium, then treated with (C) control medium; (D)
50 µM, (E) 75 µM and (F) 50 µM pamidronic acid; (G) 1 µM, (H) 10 µM and (I) 30 µM zoledronic acid,
respectively, for 7 days. Representative images used.
3.4. Hydroxyapatite Granules Prevent Pamidronic Acid and Zoledronic Acid Toxicity in 2D
As the toxicity limits were now defined, the ability of commercially available HA granules to
reduce BP toxicity was examined. Figure 4A shows the metabolic activity of human oral fibroblasts
treated with media containing PA or ZA that had been previously incubated with or without HA
granules. PA and ZA were toxic to fibroblasts but pre-incubation of a BP-containing medium with HA
granules inhibited BP toxicity to fibroblasts, as shown by significantly higher metabolic activities in
comparison to the controls. There were no significant differences between untreated (0 µM) control
cells and the untreated cells cultured with HA, indicating that the HA granules themselves were not
affecting metabolic activity.
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Figure 4. (A) Human oral fibroblast and (B) immortalised human oral keratinocyte metabolic
activity over 72 h in the presence of pamidronic acid and zoledronic acid, measured by MTT
assay. Bisphosphonates had previously been incubated for 72 h with hydroxyapatite (HA) granules;
bisphosphonates incubated with no hydroxyapatite used as a control. Values normalised to control
0 µM. N = 3, n = 3. Error bars = SD. Significance against control indicated by * p ≤ 0.05.
Figure 4B shows themetabolic activity of immortalised keratinocytes following the same treatment
as above. In the control group (no HA), dose-dependent toxicity was seen after 72 h, with both drugs
reducing metabolic activity. HA granules inhibited this reduction in metabolic activity. However,
variation was high, and no significant differences were seen between any HA groups and their
corresponding control groups.
3.5. Hydroxyapatite Prevents Zoledronic Acid Toxicity in 3D
To assess HA effects on BP toxicity in a closer representation of the in vivo scenario,
three-dimensional oral mucosa models were cultured. Oral mucosa models were cultured for
7 days at ALI before being treated with 30 µM ZA in the presence of HA granules; models with no HA
present were used as controls.
Figure 5A shows the metabolic activity of oral mucosa models treated with ZA, with and without
HA granules, after 10 days in culture. Metabolic activity values were normalised to day 7 values
(before BP and HA treatment). As expected, treatment of the models with 30 µM ZA but without HA
reduced the metabolic activity by approximately 50%. However, the models cultured with both ZA
and HA had a metabolic activity close to 100%.
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Figure 5. The metabolic activity of oral mucosa models when treated with control medium or 30 µM
zoledronic acid in the presence of hydroxyapatite granules at (A) 10 days and (B) 14 days. Models
with no HA cultured as controls, measured with a resazurin assay. Blank well reading subtracted from
values before normalising to day 7 values for each model, defining day 7 values as 100 % (not shown).
N = 3, n = 2. Error bars = SD. Statistical significance against control indicated by * p ≤ 0.05. (C–F) H
& E-stained sections of oral mucosa models seeded with human oral fibroblasts and primary human
oral keratinocytes cultured at ALI for 7 days in control medium, then treated with (C) control medium,
(E) 30 µM zoledronic acid, (D) control medium and HA granules and (F) 30 µM zoledronic acid and
HA granules, respectively, for 7 days. Representative images used.
At day 14 (Figure 5B), the metabolic activity of the control models remained at approximately
90% and treatment with 30 µM ZA reduced metabolic activity to <5%. Culture with HA granules and
30 µM ZA resulted in a significantly higher metabolic activity than those treated with the drug alone
(approximately 90%).
Further analysis of these models showed that a multi-layered epithelium was present at 14 days
when cultured in controlmedia (Figure 5C) ormedia containingHAgranules (Figure 5D).Models treated
with 30 µM ZA had no epithelium remaining (Figure 5E). However, when HA granules were
present, a stratified epithelium was present across the sample (Figure 5F), with some damage to the
superficial layer.
4. Discussion
We have demonstrated that clinically relevant concentrations of PA and ZA reduce the metabolic
activity of cells from the human oral mucosa in a dose-dependent manner. Our data showed that
both fibroblasts and keratinocytes were negatively affected by BPs. This supports the hypothesis
that BPs impair soft tissue wound healing and reduce cell viability, which in turn contributes to the
development of MRONJ.
PA and ZA have previously been demonstrated to be toxic to human oral fibroblasts and
keratinocytes, with ZA showing more cytotoxicity [10–13,16,27–34]. However, these studies used cells
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from a variety of sources, examined different concentration ranges and treatment lengths, and used
different assays to measure viability and therefore defining a toxic concentration for these drugs is
difficult. Here, we have performed a comprehensive study of the toxicity of two BPs most commonly
associated with MRONJ to allow for a more direct comparison between two drugs and two different
cell types. The concentration of BPs the oral mucosa is exposed to in the clinical situation is difficult to
measure. However, it has been estimated that the concentration of PA in bone is 2000 µM [35] and
the salivary ZA concentration of patients with osteonecrosis is between 0.4 and 5 µM [25]. We have
tested values within this range and demonstrated that concentrations toward the lower end can cause
significant soft tissue cytotoxicity, and defined IC50 values that will be important in defining limits for
the reduction in BPs in the treatment of MRONJ.
In our in vitro system, we cultured oral mucosa models for 7 days to generate an established,
multi-layer epithelium representative of the oral mucosa prior to MRONJ. PA and ZA treatments
caused the established epithelia to thin in a dose-dependent manner that was in line with previous
studies which showed that 10 µM PA and 4 to 10 µM ZA reduced epithelial thickness in oral mucosa
models [15,16,18,32]. In addition to this morphological observation, we were able to measure the
reduction in metabolic activity to quantify the negative effects that these drugs have on cell viability.
As well as reducing epithelial thickness, we observed disruption to the integrity of the epithelium,
which may be a result of changes in epithelial cell adhesion. A reduction in desmoglein-1 expression
and disruption to desmosome morphology has previously been observed in the oral mucosa of patients
receiving alendronate [36].
BPs have been found in the saliva of patients receiving BP therapy and, following dental
interventions, it is expected that some BPs bound to the bone matrix will be released into the local oral
environment, increasing the local concentration of BPs to which the oral mucosa will be exposed [37].
Here, we have shown that exposure to aqueous BPs leads to a thinner more fragile epithelium with
reduced metabolic activity. These changes will reduce the oral mucosa’s ability to repair following
damage and may explain how spontaneous cases of MRONJ occur [38], as the epithelium is more
susceptible to damage from mechanical forces and infection.
Hydroxyapatite is an osteoconductive material currently used for bone regeneration applications
including socket repair. Given the high affinity of BPs to calcium, it was hypothesised that HA (a form
of calcium phosphate) could bind BPs found in the oral cavity, reducing the bioavailability of these
drugs and limiting their damage to surrounding soft tissues. We demonstrated that incubation with
HA granules reduced fibroblast toxicity from ZA and PA, in line with recent work by Paulo et al. [21].
PermaBone® granules were used, as they are clinically available, highly porous and comprised of
pure HA and, therefore, due to the well reported BP binding relationship [5,6], it was thought they
would bind BPs. The porosity of PermaBone® HA that results in a high surface area can be seen in
Figure 1—this maximised the amount of BP that can bind to the HA. Incubation with the same weight
of HA in a pressed, sintered disc rather than in porous granules did not show the same effect (data not
shown), demonstrating that surface area is important and supporting the hypothesis that BPs bind to
the surface of the HA, rendering them incapable of exerting their damaging effects.
When immortalised keratinocytes were cultured in medium that had been incubated with HA
granules, there was large variation in the data, particularly in those also treated with PA and ZA.
Extracellular calcium concentration is known to affect differentiation, morphology and proliferation in
skin keratinocytes [39]. In addition, calcium and ZA have been shown to have a synergistic effect on
skin keratinocyte viability, as higher cellular calcium caused increased BP potency [27]. Therefore, the
variations observed in the data here are thought to be as a result of changes in calcium levels following
incubation with HA granules. Despite these variations, the metabolic activity of keratinocytes was
higher in all the samples incubated with HA granules compared to controls, so we proceeded to test
this in the 3D oral mucosa models.
When oral mucosamodels were cultured in the presence of ZA, HA granules provided a protective
effect. The metabolic rate of cells in the oral mucosa model treated with HA and ZA were comparable
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to the models without ZA treatment, while histology showed that the epithelial integrity was intact.
There was some damage to the superficial layers of the epithelium. However, the addition of HA
granules resulted in a clear improvement compared to the epithelium treated with ZA alone, which
was entirely lost.
This study has demonstrated that HA granules can bind sufficient quantities of BPs to reduce soft
tissue damage, which indicates its potential as a preventative therapy for MRONJ. Further research is
now required to determine the most clinically feasible formulation of HA for this application and to
evaluate how BP adsorption affects HA granule resorption and bone regeneration.
5. Conclusions
We have demonstrated that hydroxyapatite can be used to inhibit BP toxicity to the oral mucosa
in vitro. The application of porous HA granules to reduce BP concentrations following oral surgery
presents a potential strategy for the prevention of MRONJ in high-risk patients receiving nitrogen
containing BPs such as ZA and PA.
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